37 results about "Pigmented retinal epithelium" patented technology

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

The application relates to the technical field of ophthalmic surgical instruments, in particular to an ophthalmic internal limiting membrane tampon, which can protectively and automatically rebound when the tampon is operated with excessive force during a'mechanical' tampon process, so as to prevent iatrogenic retinal pigment epithelial layer damage at the bottom of a macular hole. The device comprises a sleeve-shaped handle, a spring and a probe are arranged in the handle along the length direction of the handle; the probe comprises a probe main body and a probe base, and the two ends of the probe base are connected with the spring and the probe main body respectively; an outer thread is arranged on the outer side of the probe base, and a tensioning wheel is arranged on the handle; the outer thread is divided into at least three thread regions arranged along the length direction of the probe base, including a first thread region, a second thread region and a third thread region; the threads in the first thread region, the second thread region and the third thread region correspond to first threads, second threads and third threads respectively; and the diameters of the second threads are all larger than the diameters of the first threads and the third threads.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting retina cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

Provided herein are compositions comprising peptides, pharmaceutical preparations thereof, and methods of using the same to prevent photoreceptor death and protect retinal cells (including but not limited to photoreceptors and retinal pigment epithelium) from Fas- or TRAIL-mediated apoptosis.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

A rhegmatogenous retinal detachment (RRD) occurs when a tear in the retina leads to fluid accumulation with a separation of the neurosensory retina from the underlying retinal pigment epithelial (RPE); this is the most common type of retinal detachment and can lead to blindness. The present invention features an eye shape modification (ESM) system (a scleral buckle) for the prevention and repair of retinal detachment as well for the adjustment of refractive error and the prevention of induced refractive error caused by scleral buckles. The present invention creates a scleral buckle with protuberances on the interior surface of the buckle. These protuberances produce corrugation / indentations in the eye which allows for both axial and circumferential relaxation. Additionally, the present invention creates on scleral buckle that remove excess bulky material from the scleral buckle band, producing a scleral buckle that is easier and safer to surgically implant onto the eye.

The recombinant AAV capsid protein is characterized in that the recombinant AAV capsid protein is obtained by mutating a common region of natural AAV5 capsid proteins VP1, VP2 and VP3; or the natural AAV5 capsid protein is heterozygous with other AAV serotype capsids, and then a common region of VP1, VP2 and VP3 is mutated, wherein the mutation point corresponds to at least one mutation from the 310th site to the 736th site of the AAV5 capsid protein of SEQ ID NO: 1; the capsid protein is targeted to the retinal pigment epithelium through intravitreal delivery, the problems that in the prior art, delivery is difficult, and retinal pigment epithelium cells cannot be effectively transduced are solved, and the AAV capsid protein has high transduction rate and immune escape capacity.

This invention relates to a self-assembling polypeptide for regulating the permeability of retinal pigment epithelium (RPE), its preparation method, and its applications. The self-assembling polypeptide comprises an integrin receptor-targeting peptide, a self-assembling polypeptide, and a hydrophobic molecule sequentially linked. The self-assembling polypeptide designed in this invention can self-assemble into nanoparticles and specifically target RPE cells. After interacting with receptors on the cell membrane, the nanoparticles transform into nanofibers, achieving rapid targeted enrichment of RPE tissue. Furthermore, by regulating the permeability of RPE tissue, it can enhance the transcellular drug transport capacity, providing a new clinical application strategy for the treatment of macular neovascularization, especially polypoid choroidal vascular lesions.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

The present invention provides a method of a prophylaxis or a treatment of a pathological change of Bruch's membrane and / or an adjacent tissue, including a retinal pigment epithelium, a choroid, and an optic nerve head of an eye, e.g. a calcification of Bruch's membrane and / or the adjacent tissue, using a nanoparticle comprising a scaffold comprising a biodegradable material, an antibody targeted to a component of a Bruch's membrane, a component of a sub-retinal pigment epithelial deposit, or a component of an optic nerve head, and an anti-calcifying agent. Additionally, the present invention provides a pharmaceutical composition comprising said nanoparticle and one or more pharmaceutical acceptable excipient(s). Said pharmaceutical composition could be used in a method of prophylaxis or treatment of a pathological change of Bruch's membrane and / or adjacent tissues, including a retinal pigment epithelium and a choroid of an eye and / or a calcified sub-retinal pigment epithelium deposit and / or a calcified drusen.

A method of detecting one or mor change in an eye and method diagnosing or proving an indication of an eye disease or eye condition or a neurogenerative disease or condition, or a predisposition thereto are disclosed. The method of detection comprises comparing an image of the eye with at least one asynchronous image of the eye to thereby detect the one or more change in the eye wherein the change comprises a darkening or lightening in pigment of the Retinal Pigment Epithelium (RPE) in the macula. The method of diagnosing or providing an indication of an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto comprises the same comparison and when the change is detected, providing a diagnosis of indication of or predisposition to an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto.

In certain embodiments, an apparatus for performing a subretinal injection into a subretinal space between a retina and retinal pigment epithelium of an eye is provided. The apparatus includes an injection needle (110) having a proximal end (112) and a distal end (114) configured to be inserted into the subretinal space at a location on a surface of the retina. The apparatus includes a multi-lumen tube (120) having a distal end (122) coupled to the proximal end (112) of the injection needle (110) and a proximal end coupled to a fluid control unit. The apparatus includes a stabilizer (130) configured to secure the injection needle (110) at the location on the surface of the retina. The fluid control unit has a plurality of fluid reservoirs containing a non-treatment solution, a treatment solution, and a working fluid that are injectable into the eye via separate lumens (128a, 128b, 128c) of the multi-lumen tube (120).

FIELD: ophthalmology.SUBSTANCE: used for objective differential diagnostics of the anatomical form of the optic nerve disc (OND) deepening. Optical coherence tomography is performed on the Optovue RTVue XR Avanti System using the 3D Disc program. Images of the optic disc are obtained in the horizontal plane, a straight line is drawn between the visible boundaries of the retinal pigment epithelium (RPE) and the position and shape of the bottom of the OND deepening are assessed. When the depression is at the level of the RPE and the angle of its bottom is less than or equal to 90° a triangular shape is defined. If the depression is located above the RPE level and the angle of its bottom is more than 90° a flat shape is defined. If the depression is below the RPE level and the bottom angle is less than or equal to 90° a wedge shape is defined. If the depression is below the RPE level, and its bottom forms a base and two angles, a trapezoidal shape is defined.EFFECT: improving the accuracy, objectivity and reproducibility of determining the individual anatomical shape of the OND excavation by using a stable anatomical landmark – the RPE and standardized geometric parameters, which eliminates subjective error in diagnosis.1 cl, 7 dwg, 1 tbl, 3 ex

A method of treating and / or preventing disease involving retinal pigment epithelium, including administering compound of formula (I)or a pharmaceutically acceptable salt, a racemic mixture, a corresponding enantiomer or a corresponding diastereomer thereof, wherein: R1, R11 and R12 are independently selected from the group consisting of hydrogen, fluoro, chloro, methoxy, trifluoromethyl, methyl and difluoromethoxy, whereby at least one of R1, R11 and R12 is not hydrogen, B is selected from the group consisting of a residue of formula (II), (III), (IV), (V), (VI) and (VII)wherein, “*” denotes point of attachment to remainder of the molecule, and R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V are independently selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl and difluoromethoxy.

The present disclosure provides a method for obtaining RPE (retinal pigment epithelium) cells from iPSCs (induced pluripotent stem cells). The method involves: (a) generating embryoid bodies from a culture of iPSCs, in which the embryoid bodies are in non-adherent suspension culture, (b) plating the embryoid bodies on a culture dish coated with a suitable extracellular matrix in differentiation induction media (DIM), in which the DIM contains at least one WNT pathway inhibitor and at least two SMAD pathway inhibitors, (c) culturing the neuroectoderm lineage in differentiation propagation media (DPM) for rosette formation, (d) culturing the rosettes of step (c) in Retinal Pigment Epithelium Maturation Media (RPEMM) to facilitate retinal progenitor cells formation, and (e) plating the retinal progenitor cells of step (d) on a culture dish coated with suitable extracellular matrix in RPEMM to obtain RPE cells.

The present invention relates to a method for treating and / or preventing diseases involving the retinal pigment epithelium, which comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, a racemic mixture, a corresponding enantiomer, or, where appropriate, a corresponding diastereomer: [Formula 1] TIFF2023549640000109.tif27151[In the formula, X is either NH or O; R 11 , R 12 and R 13 are independently selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a trifluoromethyl group, a methyl group, and a difluoromethoxy group; A is selected from the group consisting of residues of formula (II), (III), (IV), (V), (VI), (VII) or (VIII): [Case 2] TIFF2023549640000110.tif76151 (in the formula, "*" indicates the point of attachment to the rest of the molecule; R2, R3, R4, R5, R2 I , R3 I , R4 I , R5 I , R2 II , R3 II , R4 II , R5 II , R2 III , R3 III , R4 III , R5 III , R2 IV , R3 IV , R4 IV , R5 IV , R2 V , R3 V , R4 V , R5 V , R2 VI , R3 VI , R4 VI and R5 VIare independently selected from the group consisting of a hydrogen atom, a linear or branched alkyl group having 1 to 3 carbon atoms, a fluorine atom, a chlorine atom, a bromine atom, a methoxy group, an ethoxy group, a propoxy group, a trifluoromethyl group, a 2,2,2-trifluoroethyl group, and a difluoromethoxy group; In the residue of formula (VI), R6 is selected from the group consisting of a hydrogen atom, a linear or branched alkyl group having 1 to 3 carbon atoms, a trifluoromethyl group, and a 2,2,2-trifluoroethyl group.

Systems and methods described herein provide improved techniques for displaying imaging markers to verify biometric measurements. One method includes: receiving an indication to initiate a first optical coherence tomography (OCT) scan of an eye; initiating the first OCT scan of the eye based on the received indication; generating a first OCT image of the eye based on the first OCT scan; detecting a retinal pigment epithelium (RPE) and a fovea in the eye based on the first OCT image; displaying, to a user, a first augmented OCT image based on such detection, the first augmented OCT image displaying: a first virtual marker that segments at least a portion of the detected RPE; and a second virtual marker, wherein the second virtual marker visually identifies a location of the detected fovea, and wherein the second virtual marker is a radial line through the location of the detected fovea.

Systems and methods for quantifying biomarkers associated with ophthalmological elements identified via OCT imaging. A set of optical coherence tomography (OCT) volumes is received, each OCT volume corresponding to a different timepoint in a set of timepoints, and each OCT volume comprising a set of OCT B-scans. For each OCT volume of the set of OCT volumes, a set of element images is generated that visually identifies ophthalmological elements using ophthalmological element indicators. The ophthalmological element indicators assign a different group of pixels to each ophthalmological element of the plurality of ophthalmological elements. The ophthalmological elements include a target retinal element, a retinal pigment epithelial (RPE) layer, and a vitreous body. A reflectivity score is computed for the target retinal element identified in each OCT volume using the ophthalmological elements identified by the ophthalmological element indicators in each OCT volume to thereby form a set of reflectivity scores.

A computer-implemented method of processing repeat OCT B-scans of an region of an eye comprising a retina and a retinal pigment epithelium, RPE, confined to a first subregion of the region and vasculature confined to a second subregion, to generate cropped B-scans for use in generating OCT angiography data representing the vasculature, the method comprising processing each B-scan to generate a respective cropped B-scan by: selecting, from data elements of the B-scan, a subset of the data elements that are distributed along a representation of the RPE in the B-scan; using the selected data elements to define a respective B-scan subregion of interest that includes OCT data acquired from the second subregion containing the vasculature; and generating the respective cropped B-scan by cropping the B-scan to leave the B-scan subregion of interest, wherein each B-scan comprises an array of A-scans arrayed along a first axis of the B-scan, each of the A-scans comprising data elements arrayed along a second axis of the B-scan, and the selected data elements are used to define a respective B-scan subregion of interest relative to the selected data elements by: fitting a function to a spatial distribution within the B-scan of the selected data elements; using the fitted function to calculate a respective reference coordinate along the second axis of the B-scan; and defining the respective B-scan subregion of interest as a subregion of the B-scan having a predetermined size and a predetermined offset along the second axis of the B-scan relative to the calculated respective reference coordinate.

The present invention discloses an automatic segmentation method for OCT images and related devices. The method includes: an extraction step of extracting the stratification line information of the retinal pigment epithelium (RPE) and the choroid-sclera interface (CSI); a pixel acquisition step of extracting the pixel values near the RPE position and the CSI position of each column of the B-scan image; and an interpolation step of performing interpolation and calculation according to the OCT propagation attenuation model by using the preset pixel values near the RPE position and the CSI position to obtain an initial segmentation result of the choroidal blood vessels. The automatic segmentation method for choroidal blood vessels in OCT images proposed by the present invention, based on the light propagation attenuation model of OCT, can not only improve the segmentation accuracy of choroidal blood vessels in OCT images, but also has good processing ability for B-scan images with uneven blood vessel brightness, unclear blood vessel boundaries, and poor contrast. Moreover, the calculation is simple, no denoising preprocessing is required, the speed of automatic segmentation of choroidal blood vessels can be improved, and an OCT-A image with a clear choroidal blood vessel structure can also be generated.

This invention relates generally to Anelloviridae family vectors (e.g., anellovectors) and compositions and uses thereof. The Anelloviridae family vectors can be used, e.g., to deliver an exogenous effector to the retinal pigmented epithelium (RPE) of a subject. In some embodiments, the vectors can be used to treat age-related macular degeneration (AMD).

The present application relates to a novel compound and its use as therapeutically active substance in the treatment and / or prevention of diseases which involve the retinal pigment epithelium, in particular diseases which lead to atrophy, degeneration or death of the retinal pigment epithelium, which can also lead to atrophy or loss of photoreceptors and / or retinal neovascularization.

The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serumcontaining medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.

A method of administering, by a route other than intravitreal injection, a therapeutic agent to the retinal pigment epithelium (RPE) in a subject in need of a therapeutic agent effective for the treatment of the RPE or adjacent cells comprising administering to the subject a conjugate of formula F-L-A, wherein F is a ligand that targets folate receptor α (FRα), L is a linker, and A is the therapeutic agent effective for treatment of the RPE; a conjugate of formula F-L-A; and a pharmaceutical composition comprising a conjugate of formula F-L-A and a pharmaceutically acceptable carrier.

The present invention relates to a pharmaceutical composition for use in the treatment of a disease involving undesired migration, proliferation and / or metaplasia of retinal pigment epithelium (RPE) cells in a subject wherein the pharmaceutical composition comprises at least one epidermal growth factor receptor (EGFR) antagonist.